[1] Guo J, Liu M, Yang D,et al. Phospholipase C signaling via the parathyroid hormone (PTH)/PTH-related peptide receptor is essential for normal bone responses to PTH. Endocrinology. 2010;151(8):3502-3513.[2] Bellido T, Ali AA, Plotkin LI, et al. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism.J Biol Chem. 2003;278(50):50259-50272.[3] Drake MT, Srinivasan B, Mödder UI, et al. Effects of intermittent parathyroid hormone treatment on osteoprogenitor cells in postmenopausal women.Bone. 2011; 49(3):349-355.[4] Neer RM, Arnaud CD, Zanchetta JR,et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434-1441.[5] Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003;349(13): 1207-1215.[6] Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med. 2005;353(6):555-565.[7] Vahle JL, Sato M, Long GG,et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety.Toxicol Pathol. 2002;30(3): 312-321.[8] Cosman F, Lane NE, Bolognese MA, et al. Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women. J Clin Endocrinol Metab. 2010;95(1):151-158. [9] Shoyele SA, Sivadas N, Cryan SA. The effects of excipients and particle engineering on the biophysical stability and aerosol performance of parathyroid hormone (1-34) prepared as a dry powder for inhalation. AAPS PharmSciTech. 2011; 12(1):304-311.[10] Stewart AF, Cain RL, Burr DB,et al. Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1-34, parathyroid hormone-related protein 1-36, and SDZ-parathyroid hormone 893. J Bone Miner Res. 2000;15(8):1517-1525.[11] Horwitz MJ, Tedesco MB, Gundberg C,et al. Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab. 2003;88(2):569-575.[12] Horwitz MJ, Tedesco MB, Garcia-Ocaña A,et al. Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose. J Clin Endocrinol Metab. 2010;95(3):1279-1287.[13] John MR, Widler L, Gamse R, et al. ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans. Bone. 2011;49(2):233-241.[14] Saidak Z, Brazier M, Kamel S, et al. Agonists and allosteric modulators of the calcium-sensing receptor and their therapeutic applications.Mol Pharmacol. 2009;76(6): 1131-1144.[15] Widler L, Altmann E, Beerli R, et al. 1-Alkyl-4-phenyl-6-alkoxy-1H-quinazolin-2-ones: a novel series of potent calcium-sensing receptor antagonists. J Med Chem. 2010;53(5):2250-2263.[16] Marie PJ.The calcium-sensing receptor in bone cells: a potential therapeutic target in osteoporosis. Bone. 2010; 46(3):571-576.[17] Nemeth EF.The search for calcium receptor antagonists (calcilytics). J Mol Endocrinol. 2002;29(1):15-21.[18] Fitzpatrick LA, Dabrowski CE, Cicconetti G, et al. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab. 2011;96(8):2441-2449.[19] Fisher JE, Scott K, Wei N, et al. Pharmacodynamic responses to combined treatment regimens with the calcium sensing receptor antagonist JTT-305/MK-5442 and alendronate in osteopenic ovariectomized rats. Bone. 2012;50(6): 1332-1342.[20] Kumar S, Matheny CJ, Hoffman SJ, et al. An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation. Bone. 2010;46(2):534-542.[21] Di Comite G, Morganti A.Chromogranin A: a novel factor acting at the cross road between the neuroendocrine and the cardiovascular systems. J Hypertens. 2011;29(3):409-414.[22] 吴也可, 韩向龙, 白丁.Dkk-Wnt信号通路在牙齿发育中作用的研究进展[J].牙体牙髓牙周病学杂志,2012,22(5):298-301.[23] 陈有仁,李博.骨合成促进剂治疗骨质疏松症的药物研究进展[J].医学信息,2011,(3):359-360.[24] Li X, Ominsky MS, Niu QT, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008;23(6):860-869.[25] Li X, Warmington KS, Niu QT, et al. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res. 2010; 25(12):2647-2656.[26] Padhi D, Jang G, Stouch B,et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011; 26(1): 19-26.[27] Wang FS, Ko JY, Yeh DW,et al. Modulation of Dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss.Endocrinology. 2008;149(4):1793-1801.[28] Heiland GR, Zwerina K, Baum W, et al. Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Ann Rheum Dis. 2010;69 (12):2152-2159. [29] Fulciniti M, Tassone P, Hideshima T,et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood. 2009;114(2):371-379.[30] Yao W, Cheng Z, Shahnazari M,et al. Overexpression of secreted frizzled-related protein 1 inhibits bone formation and attenuates parathyroid hormone bone anabolic effects. J Bone Miner Res. 2010;25(2):190-199.[31] Bolton JM, Metge C, Lix L, et al. Fracture risk from psychotropic medications: a population-based analysis. J Clin Psychopharmacol. 2008;28(4):384-391.[32] Gambardella A, Nagaraju CK, O'Shea PJ, et al. Glycogen synthase kinase-3α/β inhibition promotes in vivo amplification of endogenous mesenchymal progenitors with osteogenic and adipogenic potential and their differentiation to the osteogenic lineage. J Bone Miner Res. 2011;26(4):811-821.[33] Loots GG, Kneissel M, Keller H,et al. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease.Genome Res. 2005;15(7):928-935.[34] Suzuki A, Ozono K, Kubota T, et al. PTH/cAMP/PKA signaling facilitates canonical Wnt signaling via inactivation of glycogen synthase kinase-3beta in osteoblastic Saos-2 cells. J Cell Biochem. 2008;104(1):304-317.[35] Tobimatsu T, Kaji H, Sowa H, et al. Parathyroid hormone increases beta-catenin levels through Smad3 in mouse osteoblastic cells. Endocrinology. 2006;147(5):2583-2590.[36] Wan M, Yang C, Li J, et al. Parathyroid hormone signaling through low-density lipoprotein-related protein 6.Genes Dev. 2008;22(21):2968-2979.[37] Guo J, Liu M, Yang D,et al. Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation.Cell Metab. 2010;11(2):161-171.[38] O'Brien CA, Plotkin LI, Galli C, et al. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One. 2008;3(8):e2942.[39] Eijken M, Swagemakers S, Koedam M,et al. The activin A-follistatin system: potent regulator of human extracellular matrix mineralization.FASEB J. 2007;21(11):2949-2960.[40] Pearsall RS, Canalis E, Cornwall-Brady M, et al. A soluble activin type IIA receptor induces bone formation and improves skeletal integrity.Proc Natl Acad Sci U S A. 2008;105(19): 7082-7087. |